S
Singleron Biotechnologies
Integrating Molecular and Cellular Information for Clinics
About Singleron Biotechnologies
Singleron Biotechnologies is an innovative molecular diagnostic company specializing in single cell analysis techniques. The company operates in the biotechnology sector, focusing on clinical diagnosis, drug development, and health management. Singleron's core product is the GEXSCOPE single cell system, which is based on a uniquely designed microfluidic device licensed exclusively from Yale University. This system allows for high throughput single cell multiomics analysis, providing detailed insights into cellular functions and interactions.
Read full description
Singleron serves a diverse range of clients including research institutions, pharmaceutical companies, and clinical laboratories. The company operates primarily in the fast-growing single cell analysis market, which is driven by the increasing demand for personalized medicine and advanced diagnostic tools.
The business model of Singleron revolves around the sale of its proprietary single cell analysis systems and related consumables. Additionally, the company offers specialized services in single cell analysis, catering to the specific needs of its clients. Revenue is generated through product sales, service contracts, and licensing agreements.
Singleron has a strong team of over 300 full-time employees with diverse expertise, enabling rapid responses to market and customer needs. The company recently completed Series A2 financing, raising close to $30 million to further its growth and innovation efforts.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Nanjing City, China
- Employees
- 91
- Open positions
- None listed
- Dealroom signal
- 78.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, KoelnBusiness, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Mar 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Singleron Biotechnologies.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $100M | $400M | CDH Investments · ARCH Venture Partners · Firstred Capital · SB China Capital | — |
| SERIES AOther financing | Sep 2020 | $30M | $120M | Tencent · ARCH Venture Partners · Lilly Asia Ventures · China Growth Capital | — |
Growth signals
Latest recorded traffic for Singleron Biotechnologies is 2.4K monthly website visits, up 7900% over the last three months. Singleron Biotechnologies's team grew 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Sherpa Venture Partners
Series A9 investors entered at this stage
Lilly Asia Ventures
Tencent
ARCH Venture Partners
China Growth Capital
Firstred Capital
Lake Bleu Capital
CDH Investments
SB China Capital
MSA Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Singleron Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Singleron Biotechnologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.